These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9863862)

  • 1. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
    Hoetelmans RM; van Heeswijk RP; Profijt M; Mulder JW; Meenhorst PL; Lange JM; Reiss P; Beijnen JH
    AIDS; 1998 Dec; 12(17):F211-6. PubMed ID: 9863862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
    Moyle G; Boffito M; Fletcher C; Higgs C; Hay PE; Song IH; Lou Y; Yuen GJ; Min SS; Guerini EM
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1532-8. PubMed ID: 19188387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
    Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
    Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
    Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penetration of didanosine in semen of HIV-1-infected men.
    Cruciani M; Liuzzi G; Chirianni A; Audagnotto S; Bonora S; Di Biagio A; Sinicco A; Bassetti M; Gatti G
    J Antimicrob Chemother; 2006 Jun; 57(6):1244-7. PubMed ID: 16556633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
    Macha S; Brand T; Meinicke T; Link J; Broedl UC
    Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
    Stevens RC; Rodman JH; Yong FH; Carey V; Knupp CA; Frenkel LM
    AIDS Res Hum Retroviruses; 2000 Mar; 16(5):415-21. PubMed ID: 10772527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics.
    Comté L; Vrijens B; Tousset E; Gérard P; Urquhart J
    J Pharmacokinet Pharmacodyn; 2007 Aug; 34(4):549-58. PubMed ID: 17497202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Hoetelmans RM; Mulder JW; Schreij G; Hsu A; Lange JM; Beijnen JH; Meenhorst PL
    AIDS; 1999 Oct; 13(14):F95-9. PubMed ID: 10513637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
    McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
    Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
    Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
    Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
    Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.
    Bruno R; Regazzi MB; Ciappina V; Villani P; Sacchi P; Montagna M; Panebianco R; Filice G
    Clin Pharmacokinet; 2001; 40(9):695-700. PubMed ID: 11605717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.
    Elger C; Bialer M; Falcão A; Vaz-da-Silva M; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsia; 2013 Aug; 54(8):1453-61. PubMed ID: 23758485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
    AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.